Valuation: Cerenome, Inc.

Market Cap 21.96M 18.83M 17.59M 16.14M 30.34M 2.1B 30.84M 208M 81.26M 1.05B 82.44M 80.65M 3.48B P/E 2026 *
-0.64x
P/E 2027 * -1.33x
Enterprise Value 21.96M 18.83M 17.59M 16.14M 30.34M 2.1B 30.84M 208M 81.26M 1.05B 82.44M 80.65M 3.48B EV / Sales 2026 *
2.33x
EV / Sales 2027 * 1.15x
Free-Float
98.2%
Yield 2026 *
-
Yield 2027 * -
1 day+3.57%
1 week-13.78%
Current month-17.57%
1 month-14.71%
3 months-45.28%
6 months-56.42%
Current year-75.09%
1 week 3
Extreme 3
3.82
1 month 3
Extreme 3
4.16
Current year 2.9
Extreme 2.9
15.32
1 year 2.9
Extreme 2.9
23.42
3 years 2.9
Extreme 2.9
80.25
5 years 2.9
Extreme 2.9
862.5
10 years 2.9
Extreme 2.9
429,377.68
Manager TitleAgeSince
Chief Executive Officer 64 02/04/2014
Director of Finance/CFO 52 06/02/2020
Chief Tech/Sci/R&D Officer - 21/10/2025
Director TitleAgeSince
Director/Board Member 64 01/10/2002
Chairman 77 25/01/2018
Director/Board Member 66 01/01/2020
Date Insider Type Main position Quantity % Market Cap.
1/7/26 Fiscal year

Director

1,844 0.0269%
1/7/26 Fiscal year

Chief Financial Officer

5,970 0.0870%
1/7/26 Fiscal year

Director

1,844 0.0269%
Change 5-day change 1-year change 3-year change Capi.($)
+3.57%-13.78%-75.61%-94.52% 21.96M
+0.95%+1.89%+1.99%+24.20% 50.5B
-0.62%+4.58%+487.47%+624.71% 46.01B
+2.09%+4.96%+20.59%+95.21% 42.85B
+3.85%+3.13%+29.60%+16.50% 41.03B
-0.72%-3.91%+17.87%+47.98% 32.02B
+3.04%+1.89%+31.62%+143.62% 16.98B
+4.33%+1.63% - - 17.05B
+1.92%+2.80%+4.71%+34.04% 14.3B
+3.87%+1.98%+82.99%+45.80% 13.84B
Average +2.22%+0.43%+66.80%+104.17% 27.46B
Weighted average by Cap. +1.62%+2.37%+104.63%+154.59%

Financials

2026 *2027 *
Net sales 9.44M 8.1M 7.56M 6.94M 13.04M 902M 13.26M 89.21M 34.93M 452M 35.44M 34.67M 1.5B 19.14M 16.42M 15.33M 14.07M 26.45M 1.83B 26.89M 181M 70.84M 918M 71.87M 70.31M 3.03B
Net income -34.22M -29.35M -27.41M -25.14M -47.28M -3.27B -48.06M -323M -127M -1.64B -128M -126M -5.42B -18.45M -15.83M -14.78M -13.56M -25.5M -1.76B -25.92M -174M -68.3M -885M -69.29M -67.79M -2.93B
Net Debt - -
Logo Cerenome, Inc.
Plus Therapeutics, Inc. is a healthcare company developing and commercializing precision diagnostics and targeted radiopharmaceuticals for central nervous system (CNS) cancers. Its subsidiary CNSide Diagnostics, LLC, develops and commercializes proprietary laboratory-developed tests, such as CNSide, designed to identify tumor cells that have metastasized to the central nervous system in patients with carcinomas and melanomas. Its lead radiotherapeutic candidate, REYOBIQ (rhenium (186Re) obisbemeda), is designed specifically for CNS cancers including GBM, LM, and pediatric brain cancers (PBC) by direct localized delivery utilizing approved standard-of-care tissue access such as with convection-enhanced delivery (CED) and intraventricular brain (Ommaya reservoir) catheters. Its radiotherapeutic candidate, Rhenium-188 NanoLiposome Biodegradable Alginate Microsphere, is designed to treat many solid organ cancers, including primary and secondary liver cancers by intra-arterial injections.
Employees
28
Date Price Change Volume
19/08/26 US$3.190 +3.57% 51,425
18/08/26 US$3.080 -3.75% 92,586
17/08/26 US$3.200 -13.04% 272,032
14/08/26 US$3.680 -0.54% 109,031
13/08/26 US$3.700 0.00% 62,111
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
3.190USD
Average target price
36.00USD
Spread / Average Target
+1,028.53%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. CNSY Stock